How is the FDA increasing transparency around Competitive Generic Therapy approvals?

The FDA’s Office of Generic Drugs has begun publishing a biweekly roster listing all ANDAs granted Competitive Generic Therapy designation, including details like approval dates, exclusivity status, and forfeitures. This public table helps stakeholders track which generics gain or lose CGT exclusivity and assess how quickly competition enters smaller drug markets.